Denmark Awards DKK 903 Million Pharmaceutical Framework Contracts to Astellas, Janssen-Cilag and Bayer Materials and Products

Standfirst

Denmark has awarded three pharmaceutical supply contracts under the Amgros 2027 1.1491.a procurement, with Astellas Pharma A/S, Janssen-Cilag A/S and Bayer A/S selected across three separate lots. The contracts have a combined tender value of approximately DKK 903 million excluding VAT. The procurement covers medicines for use by public hospital pharmacies across Denmark, with the framework arrangements scheduled to begin on 1 April 2027. The maximum value of the framework agreements is DKK 1.76085 billion, reflecting uncertainty in future medicine consumption and treatment requirements.

Introduction

Amgros I/S has completed a major Danish pharmaceutical procurement covering three medicines intended for patient treatment in public hospitals. The procurement, identified as Amgros 2027 1.1491.a, was conducted through an open procedure under Directive 2014/24/EU. The procurement is structured as three independent lots, allowing suppliers to bid for one, several or all of the individual pharmaceutical product contracts. Astellas Pharma A/S, Janssen-Cilag A/S and Bayer A/S were selected as winners for Lots 1, 2 and 3 respectively. The combined tender values reported for the three awarded lots total DKK 903 million excluding VAT.

Why This Contract Matters

The procurement is significant because it supports the supply of medicines to Denmark's public hospital pharmacy system. Amgros acts as a central purchasing body for Denmark's five regions and uses framework agreements to facilitate pharmaceutical procurement for regional hospital pharmacies. The notice states that the medicines may also potentially be resold to the Faroe Islands and Greenland. Importantly, the framework agreements are non exclusive and do not impose a purchase obligation on the hospital pharmacies, meaning actual consumption can vary from the estimated quantities.

The procurement also demonstrates how pharmaceutical purchasing can incorporate considerable demand uncertainty. Amgros explains that recommendations and treatment guidelines from the Danish Medicines Council can influence which medicines are used for particular patient populations. Changes in treatment practice, new indications and agreed prices can therefore affect consumption during the framework period.

Contract Timeline

The result notice was dispatched on 21 September 2026 and published in the Official Journal of the European Union under publication number 650606-2026 in OJ S183/2026 on 22 September 2026. The three contracts were concluded on 21 September 2026. The ordinary purchasing period is scheduled to run from 1 April 2027 to 31 March 2028, while the framework agreements can be extended up to four times for periods of up to six months.

Contract Overview

The procurement covers pharmaceutical products under CPV code 33600000. Three separate lots were tendered independently. Lot 1 covers enzalutamide tablets, Lot 2 covers apalutamide tablets and Lot 3 covers darolutamide tablets. The estimated value of the procurement is DKK 903 million excluding VAT and the maximum value of the framework agreements is DKK 1.76085 billion. Each lot has a maximum framework value of DKK 586.95 million.

Key Contract Details

Project Scope

The procurement covers three pharmaceutical products used in patient treatment at public hospitals. Lot 1 covers enzalutamide, with ATC code L02BB04, supplied as 40 mg tablets and an estimated quantity of 261,996 units. Lot 2 covers apalutamide, with ATC code L02BB05, supplied in tablet strengths ranging from 60 mg to 240 mg and an estimated quantity of 58,072 units. Lot 3 covers darolutamide, with ATC code L02BB06, supplied as 300 mg tablets and an estimated quantity of 108,220 units.

Amgros emphasises that the quantities stated in the tender are estimates rather than guaranteed purchase volumes. Actual consumption can differ substantially because the medicines are used to meet patient treatment needs and because recommendations from the Danish Medicines Council can influence pharmaceutical utilisation.

About the Contracting Authority

Amgros I/S is the central purchasing body identified in the notice and is governed by public law. Its contracting authority activity is health related. Amgros operates on behalf of Denmark's five regions and seeks framework agreements for medicines that can be supplied to regional hospital pharmacies.

The notice states that Amgros resells medicines to hospital pharmacies at its purchasing price with an additional charge. The framework agreements are non exclusive and regional hospital pharmacies are not required to use them.

About the Organisations Involved

Astellas Pharma A/S was selected for Lot 1. Its tender value was DKK 535,523,076. The winning tender identifier was Tilbudsnummer 47158 and the contract was concluded on 21 September 2026. No subcontracting was reported for the tender.

Janssen-Cilag A/S was selected for Lot 2. Its tender value was DKK 123,818,950 and the tender identifier was Tilbudsnummer 47160. The contract was concluded on 21 September 2026. The notice records one tender for this lot and identifies Abacus Medicine A/S as a non winning tenderer.

Bayer A/S was selected for Lot 3. Its tender identifier was Tilbudsnummer 47157 and its tender value was DKK 243,657,974. The contract was concluded on 21 September 2026.

Klagenævnet for Udbud is the organisation responsible for reviewing procurement complaints. The notice also identifies Konkurrence- og Forbrugerstyrelsen as the organisation providing additional information about review procedures.

TED provides the EU publication framework through which the award notice was published. The notice carries publication number 650606-2026 and was published in OJ S183/2026 on 22 September 2026.

Procurement Analysis

The procurement uses a three lot structure that separates individual pharmaceutical products and permits suppliers to compete independently for each product. This approach allows pharmaceutical companies to participate selectively instead of requiring one supplier to cover the entire procurement. The notice explicitly states that suppliers may submit tenders for one, several or all lots and can receive one, several or all contracts.

Price was the sole award criterion with a weighting of 100%. The framework agreements are designed without reopening competition, providing a defined contractual structure for purchases during the applicable purchasing period.

Additional Procurement Facts

• The procurement was conducted through an open procedure.
• The procurement was not financed with EU funds.
• The procurement is covered by the Government Procurement Agreement.
• No dynamic purchasing system was used.
• The framework agreement operates without reopening of competition.
• The contracts are non exclusive and do not create a purchase obligation for regional hospital pharmacies.
• The maximum framework value is higher than the estimated procurement value because consumption may change during the framework period.

Market & Industry Perspective

The award illustrates the importance of pharmaceutical procurement frameworks in maintaining structured access to medicines across public healthcare systems. For suppliers, demand is influenced not only by historical consumption but also by treatment guidelines, patient populations, medicine recommendations and changes in clinical practice.

The three products covered by the procurement are medicines within the same broad therapeutic area but are awarded through separate contracts. This creates a procurement environment where manufacturers and pharmaceutical suppliers can compete at product level while the purchasing authority retains flexibility around actual consumption.

The significant gap between the estimated value of DKK 903 million and the maximum framework value of DKK 1.76085 billion also highlights the difficulty of forecasting medicine consumption over a multi year procurement period.

Economic Significance

The three awarded tenders have a combined reported value of DKK 903 million excluding VAT. Lot 1 accounts for DKK 535.523 million, Lot 2 for DKK 123.819 million and Lot 3 for DKK 243.658 million. Together, these values represent a substantial procurement commitment associated with pharmaceutical supply to Denmark's public hospital system.

The framework structure also provides a mechanism for managing potential changes in medicine demand while establishing procurement arrangements for the participating healthcare system.

Future Procurement Opportunities

The framework's ordinary purchasing period begins on 1 April 2027 and ends on 31 March 2028. Amgros can extend each framework agreement up to four times for periods of up to six months, subject to the conditions specified in the notice. This means the framework structure can accommodate changes in purchasing requirements over an extended period.

Future pharmaceutical procurements are likely to continue reflecting changing treatment recommendations and patient needs. The notice specifically recognises that new indications, changes in treatment of patient populations and other developments can materially alter medicine consumption during the framework period.

Opportunities for Suppliers

The lot based structure provides pharmaceutical companies with the ability to target individual products rather than competing for a single consolidated contract. Suppliers can therefore assess each medicine independently and decide whether to submit for one, several or all available lots.

The procurement also demonstrates the importance of understanding healthcare demand uncertainty. Suppliers entering similar procurements should account for potential changes in consumption rather than treating estimated quantities as guaranteed volumes.

What Businesses Should Watch

• Changes to treatment recommendations issued by the Danish Medicines Council.
• New indications that can influence medicine consumption.
• Changes in patient populations and treatment practices.
• Future Amgros pharmaceutical procurement notices.
• Estimated quantities versus actual purchasing requirements.
• Framework extensions and purchasing periods.
• Price based competition in pharmaceutical supply contracts.

TendersOnTime.com Procurement Intelligence

From a procurement intelligence perspective, the Denmark award demonstrates why pharmaceutical opportunities should be monitored at product and lot level rather than only at broad sector level. A single procurement can contain several commercially distinct opportunities with different suppliers, values and product specifications. For suppliers, identifying the individual lot, ATC code, dosage form, estimated quantity and procurement timetable can be more useful than simply tracking the overall pharmaceutical category.

The structure also highlights an important distinction between estimated procurement value and maximum framework exposure. The DKK 903 million estimated value represents the procurement planning basis, while the DKK 1.76085 billion maximum value reflects the contracting authority's need to accommodate potential changes in pharmaceutical consumption. Procurement intelligence systems should therefore capture both values separately instead of treating the maximum framework amount as guaranteed revenue.

Another important supplier lesson is the 100% price based award structure. When price is the sole stated award criterion, suppliers need accurate cost modelling before tender submission. However, price strategy must be considered alongside uncertain demand because the framework does not guarantee purchases and hospital pharmacies are not required to use the agreements.

For future contracts, suppliers can position themselves by monitoring Amgros procurement cycles, pharmaceutical categories, treatment recommendations and upcoming framework expirations. Early monitoring can provide visibility into product specifications, likely quantities and procurement schedules before the next tender reaches the award stage.

The procurement also shows how healthcare procurement can evolve around changing clinical requirements. New indications, revised treatment recommendations and changing patient populations can alter consumption patterns during a framework period. For suppliers, continuous procurement intelligence is therefore relevant not only for discovering new tenders but also for understanding the commercial conditions surrounding existing and future pharmaceutical frameworks.

Supplier Takeaways

• Monitor Amgros pharmaceutical procurement opportunities at individual lot level.
• Review ATC codes, generic names, dosage forms, strengths and estimated quantities carefully.
• Do not treat estimated consumption as guaranteed purchase volume.
• Prepare competitive pricing where price is the sole award criterion.
• Monitor Danish Medicines Council recommendations that may influence product consumption.
• Track framework purchasing periods and available extension options.
• Assess opportunities across individual lots because suppliers can bid selectively.

Key Takeaways

• Amgros I/S awarded three pharmaceutical supply contracts under Amgros 2027 1.1491.a.
• The three winning suppliers are Astellas Pharma A/S, Janssen-Cilag A/S and Bayer A/S.
• The combined tender value is DKK 903 million excluding VAT.
• The maximum framework value is DKK 1.76085 billion.
• Lot 1 covers enzalutamide and was awarded to Astellas Pharma A/S for DKK 535.523 million.
• Lot 2 covers apalutamide and was awarded to Janssen-Cilag A/S for DKK 123.819 million.
• Lot 3 covers darolutamide and was awarded to Bayer A/S for DKK 243.658 million.
• The ordinary purchasing period runs from 1 April 2027 to 31 March 2028.
• Each framework can be renewed up to four times for periods of up to six months.
• Price was the 100% award criterion.

Conclusion

Denmark's Amgros 2027 1.1491.a procurement establishes pharmaceutical supply arrangements with Astellas Pharma A/S, Janssen-Cilag A/S and Bayer A/S across three independent medicine lots. With an estimated value of DKK 903 million and a maximum framework value of DKK 1.76085 billion, the procurement represents a significant public healthcare purchasing programme while retaining flexibility around actual medicine consumption.

The award also provides suppliers with a clear example of product level pharmaceutical competition where pricing, treatment guidance and changing healthcare demand can influence procurement outcomes and future opportunities.

Source: TED contract or concession award notice 650606-2026, OJ S183/2026, published 22 September 2026.